1040 Gastroenterol Nutr 2003; 36: 368-71. 8. Megraud F. H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004; 53: 1374-84. 9. Bae SH, Koh JS, Seo JK. Therapeutic efficacy of dual therapy and triple therapy for Helicobacter pylori infection in children. J Korean Pediatr Soc 1997; 41. 10. Choi IK, Lee SY, Chung KS. Effect of one- or two-week triple ther- apy with omeprazole, amoxicillin, and clarithromycin on eradica- tion of Helicobacter pylori infection in children. Korean J Pediatr Gastroenterol Nutr 2002; 5: 19-25. 11. Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter pylori Study Group [published erratum appears in Gut 1997 Aug; 41(2): 276]. Gut 1997; 41: 8-13. 12. Lam SK, Talley NJ. Report of the 1997 Asia Pacific Consensus Con- ference on the management of Helicobacter pylori infection. J Gas- troenterol Hepatol 1998; 13: 1-12. 13. NIH Consensus Conference. Helicobacter pylori in peptic ulcer dis- ease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. JAMA 1994; 272: 65-9. 14. Rerksuppaphol S, Hardikar W, Midolo PD, Ward P. Antimicrobial resistance in Helicobacter pylori isolates from children. J Paediatr Child Health 2003; 39: 332-5. 15. Duck WM, Sobel J, Pruckler JM, Song Q, Swerdlow D, Friedman C, Sulka A, Swaminathan B, Taylor T, Hoekstra M, Griffin P, Smoot D, Peek R, Metz DC, Bloom PB, Goldschmidt S, Parsonnet J, Triada- filopoulos G, Perez-Perez GI, Vakil N, Ernst P, Czinn S, Dunne D, Gold BD. Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons, United States. Emerg Infect Dis 2004; 10: 1088-94. 16. Ko JS, Yang HR, Seo JK. Detection of 23S rRNA mutation associat- ed with clarithromycin resistance in children with Helicobacter pylori infection. Korean J Pediatr Gastroenteril Nutr 2004; 7: 137-42. 17. Kim JM, Kim JS, Jung HC, Kim N, Kim YJ, Song IS. Distribution of antibiotic MICs for Helicobacter pylori strains over a 16-year peri- od in patients from Seoul, South Korea. Antimicrob Agents Chemother 2004; 48: 4843-7. 18. Cabrita J, Oleastro M, Matos R, Manhente A, Cabral J, Barros R, Lopes AI, Ramalho P, Neves BC, Guerreiro AS. Features and trends in Helicobacter pylori antibiotic resistance in Lisbon area, Portugal (1990-1999). J Antimicrob Chemother 2000; 46: 1029-31. 19. Goh KL. Update on the management of Helicobacter pylori infec- tion, including drug-resistant organisms. J Gastroenterol Hepatol 2002; 17: 482-7. J. Choi, J.Y. Jang, J.S. Kim, et al. 20. Czinn SJ. Helicobacter pylori infection: detection, investigation, and management. J Pediatr 2005; 146 (Suppl 3): 21-6. 21. Taneike I, Goshi S, Tamura Y, Wakisaka-Saito N, Matsumori N, Ya- nase A, Shimizu T, Yamashiro Y, Toyoda S, Yamamoto T. Emer- gence of clarithromycin-resistant Helicobacter pylori (CRHP) with a high prevalence in children compared with their parents. Helicobac- ter 2002; 7: 297-305. 22. Debets-Ossenkopp YJ, Herscheid AJ, Pot RG, Kuipers EJ, Kusters JG, Vandenbroucke-Grauls CM. Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxycillin, tetracycline and trovafloxacin in The Netherlands. J Antimicrob Chemother 1999; 43: 511-5. 23. Parsons HK, Carter MJ, Sanders DS, Winstanley T, Lobo AJ. Heli- cobacter pylori antimicrobial resistance in the United Kingdom: the effect of age, sex and socio-economic status. Aliment Pharmacol Ther 2001; 15: 1473-8. 24. Osato MS, Reddy R, Reddy SG, Penland RL, Malaty HM, Graham DY. Pattern of primary resistance of Helicobacter pylori to metron- idazole or clarithromycin in the United States. Arch Intern Med 2001; 161: 1217-20. 25. Torres J, Camorlinga-Ponce M, Perez-Perez G, Madrazo-De la Garza A, Dehesa M, Gonzalez-Valencia G, Munoz O. Increasing multidrug resistance in Helicobacter pylori strains isolated from children and adults in Mexico. J Clin Microbiol 2001; 39: 2677-80. 26. Kato M, Yamaoka Y, Kim JJ, Reddy R, Asaka M, Kashima K, Osato MS, El-Zaatari FA, Graham DY, Kwon DH. Regional differences in metronidazole resistance and increasing clarithromycin resistance among Helicobacter pylori isolates from Japan. Antimicrob Agents Chemother 2000; 44: 2214-6. 27. Ellenrieder V, Boeck W, Richter C, Marre R, Adler G, Glasbrenner B. Prevalence of resistance to clarithromycin and its clinical impact on the efficacy of Helicobacter pylori eradication. Scand J Gastroen- terol 1999; 34: 750-6. 28. Isomoto H, Inoue K, Furusu H, Enjoji A, Fujimoto C, Yamakawa M, Hirakata Y, Omagari K, Mizuta Y, Murase K, Shimada S, Murata I, Kohno S. High-dose rabeprazole-amoxicillin versus rabeprazole- amoxicillin-metronidazole as second-line treatment after failure of the Japanese standard regimen for Helicobacter pylori infection. Ali- ment Pharmacol Ther 2003; 18: 101-7. 29. Farup PG, Tholfsen J, Wetternus S, Torp R, Hoie O, Lange OJ. Com- parison of three triple regimens with omeprazole or ranitidine bis- muth citrate for Helicobacter pylori eradication. Scand J Gastroen- terol 2002; 37: 1374-9.